+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of enoxaparin to diminish the incidence of vascular access stenosis/thrombosis in chronic hemodialysis patients



Use of enoxaparin to diminish the incidence of vascular access stenosis/thrombosis in chronic hemodialysis patients



International Urology and Nephrology 43(2): 499-505



Enoxaparin, a low molecular weight heparin, has been shown to be a safe and effective anticoagulant to prevent clotting in the extracorporeal circulation during hemodialysis. Enoxaparin also possesses antiproliferative properties, and reduces neointimal proliferation following vascular injury in animals. Use of enoxaparin during hemodialysis may be associated with decreased myointimal proliferation and diminished vascular access stenosis or failure. The aim of our study was to test the efficacy of enoxaparin to reduce the incidence of recurrent vascular access stenosis in chronic hemodialysis patients. Twenty-nine hemodialysis patients who suffered from recurrent arteriovenous (A-V) access stenosis were studied retrospectively to compare the incidence of vascular access procedures before and during enoxaparin administration. Enoxaparin was administered intravenously as a single bolus at the start of hemodialysis. Twenty-eight patients (14 male) were analyzed. Ten required a new fistula during the study period. Observed treatment times (years/patient) were 1.20 ± 0.87 for unfractionated heparin (UFH) and 3.04 ± 2.19 for enoxaparin (P = 0.0001). Angiographic procedure rates (procedures/year) were 1.76 ± 0.92 in the UFH group and 1.30 ± 1.01 in the enoxoparin group (P = 0.0786). There were no significant differences in time to first stenosis between the two groups (P = 0.5315). One patient receiving enoxaparin developed upper gastrointestinal bleeding and a second patient sustained a subdural hematoma after a fall. Our study demonstrated a trend toward a decreased number of angiographic procedures for maintaining A-V access patency in selected chronic hemodialysis patients treated with enoxaparin in comparison with UFH as anticoagulant during dialysis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036062886

Download citation: RISBibTeXText

PMID: 20063059

DOI: 10.1007/s11255-009-9703-1


Related references

IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clinical Nephrology 56(6): 428-434, 2001

IgM-anticardiolipin antibody and vascular access thrombosis in chronic hemodialysis patients. Renal Failure 27(1): 25-30, 2005

Role of thrombophilia in vascular access thrombosis among chronic hemodialysis patients in Tunisia. Therapeutic Apheresis and Dialysis 15(1): 40-43, 2011

Atrial fibrillation linked to vascular access thrombosis in chronic hemodialysis patients. Journal of Atherosclerosis and Thrombosis 18(6): 448-453, 2011

Hyperhomocysteinaemia and vascular access thrombosis among chronic hemodialysis patients in Taiwan: a retrospective study. International Journal of Clinical Practice 60(12): 1596-1599, 2006

Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis. Nephron 92(4): 957-958, 2002

Vascular Access Thrombosis Is Not Related to Presence of Antiphospholipid Antibodies in Patients on Chronic Hemodialysis. Nephron 92(4): 957-958, 2002

Recombinant streptokinase treatment of thrombosis of the permanent vascular access in chronic renal insufficiency patients treated with periodic hemodialysis. Biotecnologia Aplicada 12(3): 195-196, 1995

Variable flow Doppler vascular access blood flow predicts vascular access thrombosis in hemodialysis patients with PTEE grafts. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 296A-297A, 2001

No association between hyperhomocysteinemia and vascular access thrombosis in chronic hemodialysis. Journal of Vascular Access 4(1): 14-20, 2003

Hyperhomocysteinemia and vascular access thrombosis in chronic hemodialysis Is there an association?. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 282A, 2000

Are you SURE about your vascular access? Exploring factors influencing vascular access decisions with chronic hemodialysis patients and their nurses. Cannt Journal 26(2): 21-28, 2018

Vascular access thrombosis in new hemodialysis patients. American Journal of Kidney Diseases 26(2): 341-346, 1995

Homocysteine and vascular access thrombosis in hemodialysis patients. Nephrology Dialysis Transplantation 14(9): A166, 1999

Vascular access thrombosis and antiphospholipids in hemodialysis patients. Journal of the American Society of Nephrology 7(9): 1418, 1996